Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 80

Results For "API"

3149 News Found

Novartis Leqvio demonstrates strong LDL-C goal achievement with reduced muscle pain
News | September 03, 2025

Novartis Leqvio demonstrates strong LDL-C goal achievement with reduced muscle pain

The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes


Revvity establishes In Vivo Imaging Center of Excellence in North Carolina
News | September 02, 2025

Revvity establishes In Vivo Imaging Center of Excellence in North Carolina

Facility designed to advance the next generation of imaging systems


India preparing to become hub for medical technology: Pharmaceuticals Secretary
Policy | September 01, 2025

India preparing to become hub for medical technology: Pharmaceuticals Secretary

Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth


Bayer presents Phase III VICTOR clinical trial data of vericiguat at ESC Congress 2025
News | August 31, 2025

Bayer presents Phase III VICTOR clinical trial data of vericiguat at ESC Congress 2025

The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged


Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity
News | August 31, 2025

Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity

Replicate will receive research funding and could potentially receive up to approximately US$550 million


FDA approves Teva Pharmaceuticals' first GLP-1 obesity drug
Drug Approval | August 29, 2025

FDA approves Teva Pharmaceuticals' first GLP-1 obesity drug

Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market


Lilly's oral GLP-1 orforglipron succeeds in Phase 3 trial
News | August 29, 2025

Lilly's oral GLP-1 orforglipron succeeds in Phase 3 trial

Triggering global regulatory submissions this year for the treatment of obesity


Sai Life Sciences completes Phase II of production block 11 at Bidar
News | August 29, 2025

Sai Life Sciences completes Phase II of production block 11 at Bidar

With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL


Zydus Therapeutics reports positive phase-3 results in rare liver disease
News | August 29, 2025

Zydus Therapeutics reports positive phase-3 results in rare liver disease

Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients